Press Releases

June 3, 2026 Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032
Read More
June 3, 2026 Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032
Read More
June 2, 2026 Celcuity’s Gedatolisib Combination Regimens Doubled the Likelihood of Survival without Disease Progression or Death Compared to Alpelisib plus Fulvestrant in the PIK3CA Mutant Cohort of the Pivotal Phase 3 VIKTORIA-1 Trial in Patients with HR+/HER2- Advanced Breast Cancer
Read More
June 1, 2026 Celcuity to Hold Conference Call to Discuss Results for the PIK3CA Mutant Cohort of the Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib Regimens in HR+/HER- Advanced Breast Cancer on June 2, 2026
Read More
May 28, 2026 Celcuity To Participate in Upcoming Investor Conferences
Read More
May 14, 2026 Celcuity Inc. Reports Release of First Quarter 2026 Financial Results and Provides Corporate Update
Read More
May 14, 2026 Celcuity’s Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients
Read More
May 7, 2026 Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference Call
Read More
May 1, 2026 Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort
Read More
March 25, 2026 Celcuity Inc. Reports Release of Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Read More